A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: Application to therapeutic drug monitoring in patients with renal cell carcinoma-Reference-Cited by-同舟云学术

A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: Application to therapeutic drug monitoring in patients with renal cell carcinoma

Published:2020-02 Issue: Volume:1138 Page:121968
ISSN:1570-0232
Container-title:Journal of Chromatography B
language:en
Short-container-title:Journal of Chromatography B

Author:

Ferrer Florent,Solas Caroline,Giocanti Madeline,Lacarelle Bruno,Deville Jean-Laurent,Gravis Gwenaelle,Ciccolini Joseph

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry

Reference16 articles.

1. METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial;Choueiri;Lancet Oncol.,2016

2. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update;Choueiri;Eur. J. Cancer,2018

3. Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma.Onco Targets;Gerendash;Ther,2017

4. Population pharmacokinetic model of cabozantinib in patients with medullary thyroid carcinoma and its application to an exposure-response analysis;Miles;ClinPharmacokinet,2016

5. A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types;Lacy;Cancer ChemotherPharmacol.,2018

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Plasma Cabozantinib Concentration With Treatment Response and Adverse Events in Japanese Patients With Advanced Renal Cell Carcinoma;Therapeutic Drug Monitoring;2024-08-29

2. Quantification and analyses of seven tyrosine kinase inhibitors targeting hepatocellular carcinoma in human plasma by QuEChERS and UPLC-MS/MS;Journal of Chromatography B;2024-07

3. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma;Clinical Genitourinary Cancer;2024-06

4. Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087);Clinical Cancer Research;2023-07-31

5. Plasma Cabozantinib Level Measurement in Patients with Renal Cell and Hepatocellular Carcinomas Using a Simple HPLC–UV Method Suitable for Clinical Application;Current Oncology;2023-05-08